The evolution of minimal residual disease: key insights based on a bibliometric visualization analysis from 2002 to

Zhengyu Yu1, Li Xie2, Jing Zhang2

  • 1Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.

Frontiers in Oncology
|August 3, 2023
PubMed
Abstract

Insights

Minimal residual disease (MRD) research has surged, with the United States leading in publications. Key areas include leukemia and myeloma detection technologies, guiding future oncology advancements.

Area of Science:

  • Oncology
  • Hematology
  • Biomedical Research

Background:

  • Minimal residual disease (MRD) detection and monitoring are critical in oncology for diagnosis, treatment, and prognosis.
  • MRD has become a significant focus in cancer research over recent years.

Purpose of the Study:

  • To conduct a bibliometric analysis of research trends, hotspots, and frontiers in MRD over the past two decades.
  • To identify key research areas and collaborations in the field of MRD.

Main Methods:

  • Bibliometric visualization analysis of 8,913 academic papers on MRD from 2002 to 2022 using Web of Science.
  • Co-occurrence, co-citation, and burst analyses of countries, institutions, journals, authors, keywords, and references using VOSviewer, CiteSpace, and RStudio.

Main Results:

  • MRD research shows a rising trend, with the United States as the dominant country and the Netherlands leading in citations per article.
  • The University of Texas MD Anderson Cancer Center is the most influential institution, and *Blood* is the leading journal.
  • Research hotspots and frontiers include MRD applications in acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and detection technologies.

Conclusions:

  • This bibliometric analysis provides insights into MRD research hotspots and trends from 2002 to 2022.
  • Findings can assist researchers in identifying collaboration opportunities and directing future research in MRD detection and monitoring.